Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HRMY Harmony Biosciences Holdings Inc
- Stocks
- Healthcare
- NASDAQ: HRMY
Price (delayed)
$35.07
Market cap
$2.01B
P/E Ratio
13.13
Dividend/share
N/A
EPS
$2.67
Enterprise value
$1.7B
Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves
Highlights
The stock's price to earnings (P/E) is 53% less than its 5-year quarterly average of 28.0 and 12% less than its last 4 quarters average of 14.9
Harmony Biosciences Holdings's equity has increased by 40% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of HRMY
Market
Valuations
Earnings
Shares outstanding
57.42M
Market cap
$2.01B
Enterprise value
$1.7B
Price to earnings (P/E)
13.13
Price to book (P/B)
2.79
Price to sales (P/S)
2.7
EV/EBIT
7.95
EV/EBITDA
7.15
EV/Sales
2.28
Revenue
$744.85M
Gross profit
$583.53M
Operating income
$195.04M
Net income
$152.72M
EBIT
$213.99M
EBITDA
$237.95M
Free cash flow
$221.39M
Per share
Balance sheet
Liquidity
EPS
$2.67
EPS diluted
$2.62
Free cash flow per share
$3.86
Book value per share
$12.56
Revenue per share
$13
TBVPS
$16.55
Total assets
$1.06B
Total liabilities
$335.01M
Debt
$175.68M
Equity
$720.53M
Working capital
$467.57M
Debt to equity
0.24
Current ratio
3.67
Quick ratio
3.5
Net debt/EBITDA
-1.32
Margins
Efficiency
Dividend
EBITDA margin
31.9%
Gross margin
78.3%
Net margin
20.5%
Operating margin
26.2%
Return on assets
15.9%
Return on equity
24.3%
Return on invested capital
47.7%
Return on capital employed
24.3%
Return on sales
28.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRMY stock price
How has the Harmony Biosciences Holdings stock price performed over time
Intraday
2.45%
1 week
3%
1 month
25.52%
1 year
19.65%
YTD
1.92%
QTD
5.66%
Financial performance
How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$744.85M
Gross profit
$583.53M
Operating income
$195.04M
Net income
$152.72M
Gross margin
78.3%
Net margin
20.5%
The company's revenue rose by 21% YoY and by 4.2% QoQ
The operating margin has declined by 21% year-on-year
The gross profit has grown by 19% YoY and by 4.6% from the previous quarter
Harmony Biosciences Holdings's net income has increased by 11% YoY and by 5% from the previous quarter
Price vs fundamentals
How does HRMY's price correlate with its fundamentals
Growth
What is Harmony Biosciences Holdings's growth rate over time
Valuation
What is Harmony Biosciences Holdings stock price valuation
P/E
13.13
P/B
2.79
P/S
2.7
EV/EBIT
7.95
EV/EBITDA
7.15
EV/Sales
2.28
The stock's price to earnings (P/E) is 53% less than its 5-year quarterly average of 28.0 and 12% less than its last 4 quarters average of 14.9
Harmony Biosciences Holdings's EPS has increased by 14% YoY and by 4.3% QoQ
The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 9.2 and 13% less than its last 4 quarters average of 3.2
Harmony Biosciences Holdings's equity has increased by 40% YoY and by 9% from the previous quarter
HRMY's P/S is 53% below its 5-year quarterly average of 5.7 and 3.6% below its last 4 quarters average of 2.8
The company's revenue rose by 21% YoY and by 4.2% QoQ
Efficiency
How efficient is Harmony Biosciences Holdings business performance
Harmony Biosciences Holdings's return on sales has decreased by 16% YoY and by 2% QoQ
The ROE is down by 14% YoY and by 3.6% from the previous quarter
HRMY's return on invested capital is down by 9% year-on-year
HRMY's return on assets is down by 8% year-on-year
Dividends
What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRMY.
Financial health
How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is up by 25% year-on-year and by 6% since the previous quarter
The quick ratio has grown by 19% YoY and by 11% from the previous quarter
The debt is 76% less than the equity
Harmony Biosciences Holdings's equity has increased by 40% YoY and by 9% from the previous quarter
The debt to equity has declined by 35% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.